Premium
Interleukin‐2 therapy of Langerhans cell histiocytosis
Author(s) -
Hirose M,
Saito S,
Yoshimoto T,
Kuroda Y
Publication year - 1995
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1995.tb13529.x
Subject(s) - medicine , langerhans cell histiocytosis , etoposide , cytarabine , cyclophosphamide , vincristine , chemotherapy , pathology , histiocytosis , disease
A 20‐month‐old girl was diagnosed with Langerhans cell histiocytosis on the basis of a seborrheic skin rash, multiple punched out bony lesions, and skin biopsy findings. Combination therapy including α‐interferon, vincristine, vindesine, cyclophosphamide, etoposide, cisplatin, betamethasone, THP‐adria‐mycin, cytarabine and methotrexate was ineffective. Because cyclophosphamide enhanced lesion growth within the skull, we administered an intravenous infusion of interleukin‐2 with remarkable efficacy. The reduction in lesion size with interleukin‐2 treatment paralleled the increase in the percentage of CD16‐positive natural killer cells in the peripheral blood. Interleukin‐2, Langerhans cell histiocytosis, natural killer cells